Novo Nordisk’s Amycretin Pill: Promising Weight Loss without Injections

Novo Nordisk’s New Weight-Loss Pill Amycretin Shows Promise

For many Americans, the weight-loss medication Ozempic has become a popular choice. However, its high cost and injection-based application have deterred some interested parties. While the price isn’t expected to decrease in the near future, Ozempic’s creator, Novo Nordisk, may have found an alternative solution for those with a fear of needles.

The pharmaceutical company has formulated a pill named Amycretin that has shown potential in inducing significant weight loss. Early trial results suggest a weight loss of up to 13% within three months.

While Amycretin is not the same as Ozempic, it works in a similar manner. Like Ozempic, Amycretin replicates the GLP-1 hormone, which helps to suppress appetite. Additionally, it mimics amylin, a hormone that promotes a feeling of fullness.

Amycretin’s Promising Trial Results

• Average weight loss of 10.4% among trial participants, compared to 1.1% in the placebo group.
• Maximum weight loss recorded at 13.1%.
• Continued potential for additional weight loss, as participants had not plateaued by the end of the treatment period.

These results could signify a new weight-loss solution for individuals who are overweight or obese but do not have diabetes. (Ozempic, in contrast, is a treatment for diabetes.)

As the researchers noted, “A single molecule that targets both amylin and GLP-1 biology in a tablet form could offer a more convenient approach to achieving better outcomes for individuals with overweight or obesity.”

Side Effects and Future Plans

Reported side effects of Amycretin were primarily mild to moderate and largely gastrointestinal, including nausea and vomiting.

The success of Ozempic has catapulted Novo Nordisk to a valuation of $500 billion. Despite competition from other weight loss drugs, the company anticipates a profit growth of 29% this year. Although Novo Nordisk has faced some supply constraints, it has announced plans to construct a “mega manufacturing facility” outside of Dublin to increase production.

While additional studies on Amycretin are needed, these preliminary findings offer a glimpse of a promising new weight loss treatment on the horizon.